Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 17.85 INR
Change Today 0.00 / 0.00%
Volume 0.0
SBML On Other Exchanges
Symbol
Exchange
SBML is not on other exchanges.
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sharon bio-medicine ltd (SBML) Snapshot

Open
18.20
Previous Close
18.45
Day High
19.35
Day Low
17.55
52 Week High
09/15/14 - 90.35
52 Week Low
07/6/15 - 12.45
Market Cap
1.9B
Average Volume 10 Days
2.3M
EPS TTM
6.66
Shares Outstanding
105.6M
EX-Date
12/11/14
P/E TM
2.7x
Dividend
0.36
Dividend Yield
2.02%
Current Stock Chart for SHARON BIO-MEDICINE LTD (SBML)

Related News

No related news articles were found.

sharon bio-medicine ltd (SBML) Related Businessweek News

No Related Businessweek News Found

sharon bio-medicine ltd (SBML) Details

Sharon Bio-Medicine Limited develops, manufactures, and sells intermediates, active pharmaceutical ingredients (APIs), and finished dosage products in India and internationally. The company provides its APIs in a range of therapeutic areas, including anti depressant, anti hypertensive, anti fungal, anti diabetic, anti bacterial, anti Alzheimer, anti psychotic, anti protozoal, anti diarrhoeal, and cardiovascular areas, as well as veterinary, pro-kinetic, NSAID, and muscle relaxation areas. Its intermediate product line targets various API/end uses, such as ketoconazole, itraconazole, phase transfer catalyst, lansoprazole, trimetazidine, chemical synthesis, glibenclamide, glimepiride, amlodipine besylate, and sertraline HCL. The company also offers formulations in the therapeutic segments of oncology, antibiotics, dermatology, liquid orals, soft gelatin capsules, and suppositories. In addition, it provides clinical services, as well as various toxicology services related to animals. Sharon Bio-Medicine Limited was incorporated in 1989 and is based in Mumbai, India.

Founded in 1989

sharon bio-medicine ltd (SBML) Top Compensated Officers

Chairman and Managing Director
Total Annual Compensation: 2.8M
Director of Operations & Business Development...
Total Annual Compensation: 2.8M
Compensation as of Fiscal Year 2014.

sharon bio-medicine ltd (SBML) Key Developments

Sharon Bio Medicine Limited, Board Meeting, Jun 10, 2015

Sharon Bio Medicine Limited, Board Meeting, Jun 10, 2015. Agenda: To consider allotment of equity shares on account of conversion of warrants.

Sharon Bio Medicine Limited, Board Meeting, May 27, 2015

Sharon Bio Medicine Limited, Board Meeting, May 27, 2015.

Sharon Bio Medicine Limited Reports Unaudited Standalone Earnings Results for Third Quarter and Nine Months Ended March 31, 2015

Sharon Bio Medicine Limited reported unaudited standalone earnings results for third quarter and nine months ended March 31, 2015. For the quarter, the company’s net sales/income from operations was INR 1,291.532 million compared to INR 3,156.854 million a year ago. Loss from operations before exchange rate difference other income, interest and exceptional items were INR 102.645 million compared to profit of INR 350.180 million a year ago. Loss from ordinary activities before tax was INR 488.462 million compared to profit of INR 197.404 million a year ago. Net loss after tax was INR 488.462 million or INR 3.00 per diluted share before and after extraordinary items compared to profit of INR 178.393 million or INR 1.69 per diluted share before and after extraordinary items for the same period a year ago. For the nine months, the company’s net sales/income from operations was INR 6,919.964 million compared to INR 9,670.095 million a year ago. Loss from operations before exchange rate difference other income, interest and exceptional items were INR 532.735 million compared to profit of INR 1,004.026 million a year ago. Loss from ordinary activities before tax was INR 1,341.110 million compared to profit of INR 579.561 million a year ago. Net loss after tax was INR 1,341.110 million or INR 8.24 per diluted share before and after extraordinary items compared to profit of INR 492.647 million or INR 4.67 per diluted share before and after extraordinary items for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBML:IN 17.85 INR 0.00

SBML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBML.
View Industry Companies
 

Industry Analysis

SBML

Industry Average

Valuation SBML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHARON BIO-MEDICINE LTD, please visit www.sharonbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.